Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals’ stock rose to a record high of $84.8, lifting its market capitalization to about $9 billion. The company reported strong revenue growth with net product revenues of $24.0 million in Q2 2026 and total revenue of $25.1 million. The planned roughly $10 billion acquisition by Vertex has advanced following regulatory approvals, but analysts reacted with downgrades. Data indicate the stock may be temporarily above its fair value and overbought. » Mais em de.investing.com

The planned takeover of Crinetics by Vertex has passed important antitrust waiting periods and received approvals in Austria, Germany and Australia. The transaction envisages a cash price of $85 per share (around $10 billion) and remains subject, among other things, to approval by Crinetics shareholders on August 28, 2026; closing is expected in early September or in the third quarter of 2026. Crinetics shares are trading near their 52-week high, and the company reported strong revenue growth for Palsonify in the second quarter of 2026. » Mais em de.investing.com

Crinetics Pharmaceuticals shares rose to a record high of $84.35 and are trading near their 52-week high; market capitalization is about $8.94 billion. Vertex announced a takeover of Crinetics for $85 per share (about $10 billion), with completion expected in Q3 2026. Crinetics reported strong revenue growth driven by Palsonify (Q2 revenue $24.0 million; total revenue $25.1 million) and has posted double-digit gains year-to-date, while some analysts have cut ratings from buy to neutral/hold and InvestingPro flags overbought RSI signals and possible overvaluation. » Mais em de.investing.com

The stock of Crinetics Pharmaceuticals reached a record high of $84.01, just above the 52-week high of $84. Over the past year the price rose 187.21%; market capitalization is about $8.85 billion. Vertex announced the acquisition of Crinetics for $85 per share (around $10 billion), after which several analysts adjusted ratings and price targets. » Mais em de.investing.com

Crinetics Pharmaceuticals shares climbed to a record high of $83.77, putting them close to their 52-week high. The stock has risen 163.21% over the past year and the market capitalization is about $8.83 billion. InvestingPro rates the stock as overvalued relative to its fair value, and the RSI points to an overbought area. At the same time, Vertex Pharmaceuticals announced it will acquire Crinetics for roughly $10 billion ($85 per share), with the deal expected to close in Q3 2026, after which several analysts downgraded their ratings on Crinetics to hold/neutral. » Mais em de.investing.com